Research
Molecular
BGM1812 is a novel dual amylin and calcitonin receptor agonist with enhanced efficacy compared to petrelintide.
BGM1812 may be a promising option for obesity treatment.
StrongSupportsmedium confidence
In both in vivo and in vitro studies, BGM1812 showed significantly enhanced efficacy.
Why this rating
The study involves in vivo and in vitro research, indicating strong evidence.
Source
Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment
Leilei Zong et al. · Journal of Medicinal Chemistry · 2025
DOI 10.1021/acs.jmedchem.5c01120
otherCited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Molecular
- QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.Strong
- Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.Strong
- The Low-Fat Plus diet resulted in a greater reduction in total cholesterol compared to the Low-Fat diet, with changes of -0.46 mmol/L (-17.6 mg/dL) versus -0.24 mmol/L (-9.2 mg/dL) respectively (P = 0.01).Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →